Study conducted by Meiji Seika Pharma in Japan Short communication follows previously published data in The Lancet Infectious Diseases demonstrating Immunological Non-Inferiority to Wuhan Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster  New data demonstrates continuous advantage of sa-mRNA over conventional mRNA vaccine in terms of duration of immune response These results follow approval of the world's first sa-mRNA COVID-19 vaccine for adults ...

MarsBars Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is an interesting biotechnology company in the clinical and commercial stages for rare and infectious diseases. Its proprietary platforms, LUNAR for lipid-mediated mRNA delivery and STARR for self-amplifying mRNA technology allowed ARCT to create COVID and influenza vaccines already approved in Japan and with MAA filed in the EU. Also, ARCT is developing game-changing therapies advancing in clinical trials, such as ARCT-810 and ARCT-032 for Ornithin ...

fatido/E+ via Getty Images Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is gearing up to report results from its phase 1b study using its inhaled messenger RNA [mRNA] treatment known as ARCT-032 for the treatment of patients with Cystic Fibrosis [CF]. There is an important catalyst to watch with respect to this program, which is that there will be the release of interim results from this phase 1b study in the 1st half of 2024. What makes this biotech unique is that its approach to treating this patient ...

Therapeutics Holdings Inc. (NASDAQ:ARCT) Q3 2023 Earnings Conference Call November 15, 2023 4:30 PM ET Company Participants Neda Safarzadeh - Vice President, Head of Investor Relations, Public Relations, Marketing Joseph Payne - President and Chief Executive Officer Andrew Sassine - Chief Financial Officer Padmanabh Chivukula - Chief Scientific Officer and Chief Operating Officer Conference Call Participants Yasmeen Rahimi - Piper Sandler Myles Minter - William Blair Seamus Fernandez - Guggenheim Carly Kens ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share ARCT The NASDAQ Stock Market LLC FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q2 2023 Earnings Conference Call August 7, 2023 4:30 PM ET Company Participants Neda Safarzadeh - VP, Head IR, Public Relations and Marketing Joseph Payne - President and CEO Andy Sassine - CFO Pad Chivukula - CSO and COO Conference Call Participants Yasmeen Rahimi - Piper Sandler Myles Minter - William Blair Evan Wang - Guggenheim Securities Pete Stavropoulos - Cantor Fitzgerald Yanan Zhu - Wells Fargo Carly Kenselaar - Citi Thomas Yip - H.C. Wainwright Yal ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38942 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact Name of Registrant as Specified in its Charter) Delaware 32-0595345 (State or oth ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants Neda Safarzadeh – Vice President, Head-Investor Relations, Public Relations and Marketing Joseph Payne – President and Chief Executive Officer Andy Sassine – Chief Financial Officer Pad Chivukula – Chief Scientific Officer and Chief Operating Officer Conference Call Participants Yasmeen Rahimi – Piper Sandler Pete Stavropoulos – Cantor Fitzgerald Evan Wang – Guggenheim Securities Ca ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38942 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact Name of Registrant as Specified in its Charter) Delaware 32-0595345 (State or ot ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2022 Earnings Conference Call March 28, 2023 4:30 PM ET Company Participants Neda Safarzadeh - IR Joseph Payne - President & CEO Andrew Sassine - CFO Padmanabh Chivukula - Chief Scientific Officer & Chief Operating Officer Conference Call Participants Seamus Fernandez - Guggenheim Yanan Zhu - Wells Fargo Securities Ashiq Mubarack - Citi Pete Stavropoulos - Cantor Fitzgerald Operator Greetings, and welcome to the Arcturus Therapeutics Fourth Quarter 2022 F ...